California Institute for Regenerative Medicine

First therapy funded by California taxpayer dollars is approved to treat rare childhood disorder

The California Institute for Regenerative Medicine (CIRM) celebrates a major milestone in the agency’s 21-year history: the first approved therapy to come out of California taxpayer funding. The U.S.
cirm.ca.gov

Steven Schwartz

Get the latest CIRM news, information on upcoming meetings, and funding opportunities delivered to your inbox.
cirm.ca.gov

Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of MZ-1866, a gene therapy for Pitt Hopkins Syndrome

Get the latest CIRM news, information on upcoming meetings, and funding opportunities delivered to your inbox.
cirm.ca.gov

Pembrolizumab and a Vaccine (ATL-DC) for the Treatment of Surgically Accessible Recurrent Glioblastoma

Get the latest CIRM news, information on upcoming meetings, and funding opportunities delivered to your inbox.
cirm.ca.gov

T-Cell Therapy (ECT204) in Adults With Advanced HCC

Get the latest CIRM news, information on upcoming meetings, and funding opportunities delivered to your inbox.
cirm.ca.gov

CIRM announces Tools and Technologies Grants to remove obstacles on the path to therapies

Irvine, Calif., December, 10, 2008 – The California Institute for Regenerative Medicine (CIRM), the state stem cell agency, will be funding 23 grants to 18 institutions aimed at generating new tools ...
cirm.ca.gov

A Study of Deramiocel (CAP-1002) in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy

Get the latest CIRM news, information on upcoming meetings, and funding opportunities delivered to your inbox.
cirm.ca.gov

A Study of Dazostinag as Single Agent and Dazostinag in Combination With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors

Get the latest CIRM news, information on upcoming meetings, and funding opportunities delivered to your inbox.